Related references
Note: Only part of the references are listed.Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report
Atsuko Ashida et al.
ACTA DERMATO-VENEREOLOGICA (2016)
Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma
Max Schreuer et al.
MELANOMA RESEARCH (2016)
Quantitative Cell-Free Circulating BRAF(V600E) Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors
Miguel F. Sanmamed et al.
CLINICAL CHEMISTRY (2015)
Significance of Allelic Percentage of BRAF c.1799T > A (V600E) Mutation in Papillary Thyroid Carcinoma
Shih-Ping Cheng et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients
Miguel F. Sanmamed et al.
CLINICA CHIMICA ACTA (2014)
Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Geoffrey R. Oxnard et al.
CLINICAL CANCER RESEARCH (2014)
Minimal Residual Disease in Breast Cancer: In Blood Veritas
Giulia Siravegna et al.
CLINICAL CANCER RESEARCH (2014)
Is a Single BRAF Wild-Type Test Sufficient to Exclude Melanoma Patients from Vemurafenib Therapy?
Melanie Saint-Jean et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Systemic treatment for BRAF-mutant melanoma: where do we go next?
Alexander M. Menzies et al.
LANCET ONCOLOGY (2014)
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
Alain R. Thierry et al.
NATURE MEDICINE (2014)
Digital PCR as a Novel Technology and Its Potential Implications for Molecular Diagnostics
Jim F. Huggett et al.
CLINICAL CHEMISTRY (2013)
Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients
Valerie Taly et al.
CLINICAL CHEMISTRY (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Quantitative Identification of Mutant Alleles Derived from Lung Cancer in Plasma Cell-Free DNA via Anomaly Detection Using Deep Sequencing Data
Yoji Kukita et al.
PLOS ONE (2013)
Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level
K. Sakaizawa et al.
BRITISH JOURNAL OF CANCER (2012)
Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples
Audrey Didelot et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2012)
BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
Maria Colombino et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Assessment of BRAF and KIT mutations in Japanese melanoma patients
Atsuko Ashida et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2012)
Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas
Kazuya Taniguchi et al.
CLINICAL CANCER RESEARCH (2011)
Evaluation of multiple serum markers in advanced melanoma
Angel Diaz-Lagares et al.
TUMOR BIOLOGY (2011)
Cell-free nucleic acids as biomarkers in cancer patients
Heidi Schwarzenbach et al.
NATURE REVIEWS CANCER (2011)
Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer
Nikolas H. Stoecklein et al.
CANCER CELL (2008)
Circulating mutant DNA to assess tumor dynamics
Frank Diehl et al.
NATURE MEDICINE (2008)
Evaluation of 5-S-cysteinyidopa as a marker of melanoma progression:: 10 years' experience
K Wakamatsu et al.
MELANOMA RESEARCH (2002)
Share Paper
